{"links":{"feed":"https://www.erudio.com/reports/dareon-nec-1-nct07544654/feed.json","html":"https://www.erudio.com/reports/dareon-nec-1-nct07544654","json":"https://www.erudio.com/reports/dareon-nec-1-nct07544654.json","markdown":"https://www.erudio.com/reports/dareon-nec-1-nct07544654.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dareon-nec-1-nct07544654"}},"request":"https://www.erudio.com/contact?report=dareon-nec-1-nct07544654"},"offer":{"cited_clinicians":3,"cited_commentary_sources":6,"verified_hcp_statements":58,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"dareon-nec-1-nct07544654"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dareon-nec-1-nct07544654","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dareon-nec-1-nct07544654","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 58 verified statements · 41 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-15T08:45:22.473973Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: 58 verified statements (was 54); 41 statements from speakers with a confirmed clinical role (was 38); 9 findings (was 8); finding titles; per-finding counts; publication caveats beside findings; trial aspects; section headings; source breakdowns; the indications and therapeutic areas the report is listed under; the limitations; source quotations and links in the paid report. Finding titles on this page say what speakers discuss, with no word judging benefit or harm; the report keeps its own titles."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":11,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":3,"title":"DLL3 assessment, treatment rationale and adoption infrastructure"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":1,"title":"Eligibility and initial regimen choices"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":2,"title":"Participation trade-offs, equitable access and patient support"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":3,"title":"Time-specific recruitment and site access"},{"claim_count":4,"coverage":"discussed","id":"A5","source_count":2,"title":"Earlier DAREON-7 activity and unresolved DLL3 subgroup questions"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":1,"title":"Maintenance hopes informed by small-cell lung cancer"},{"claim_count":2,"coverage":"discussed","id":"A7","source_count":1,"title":"Commercial positioning and conditional class-wide interpretations"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":4,"cited_clinicians":3,"cited_clinicians_by_role":{"physician":1,"physician, Hematology and oncology":1,"physician, Medical oncology":1},"cited_physicians":3,"cited_sources":6,"claims_by_expression_type":{"comparison":3,"experience":3,"interpretation":7,"opinion":15,"question":3,"restatement":21,"uncertainty":3,"unspecified":3},"claims_by_kind":{"source_observation":58},"clinician_statements":41,"evidence_units":20,"findings":9,"organisational_accounts":1,"people_cited":4,"people_identity_verified":4,"people_total":5,"screened_sources":10,"verified_claims":58},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":2,"views":3},"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":1,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"One clinician hopes for longer control, survival and preserved quality of life while warning benefit remains uncertain","evidence_line":"8 statements from 1 speaker in 2 sources, all podcasts or videos"},{"cited_clinicians":1,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":1},"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":5,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"One X account questions what a survival win would mean when treatment durations differ","evidence_line":"7 statements from 1 speaker in 2 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":2},"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"One clinician warns that initial regimen choices and DLL3 testing can determine trial access","evidence_line":"9 statements from 1 speaker in 1 source, a podcast or video"},{"cited_clinicians":1,"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":5,"views":2},"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"One clinician says CRS appears mostly manageable but stresses intensive early monitoring","evidence_line":"9 statements from 1 speaker in 1 source, a podcast or video"},{"cited_clinicians":1,"id":"F5","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":2,"views":8},"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":1,"passages":5,"sources":2,"sources_by_kind":{"media":2}},"title":"One clinician acknowledges local chemotherapy as a real counterweight to trial enrollment","evidence_line":"13 statements from 1 speaker in 2 sources, all podcasts or videos"},{"cited_clinicians":0,"id":"F6","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One X account anticipates DLL3 workflow and specialist-readiness barriers to adoption","evidence_line":"2 statements in 1 source"},{"cited_clinicians":2,"id":"F8","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One X account hopes lung-cancer maintenance results can be replicated in epNEC","evidence_line":"2 statements from 2 speakers in 1 source"},{"cited_clinicians":0,"id":"F9","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One X account reads indication selection as competitive positioning and predicts class-wide stakes","evidence_line":"2 statements in 1 source"},{"cited_clinicians":1,"id":"F7","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"One account discusses phase Ib DAREON-7 responses and DLL3-high PFS pending randomized survival evidence; another relays a question about increased CRS with high DLL3","evidence_line":"4 statements from 2 speakers in 2 sources"}],"open_question":{"basis":"From finding F1 (8 statements from 1 speaker in 2 sources)","cited_claim_ids":["claim-6181ea52588a8937a7a7","claim-6d87349067cd3d452232","claim-da65e403acb71a7e2e70","claim-eaffa0922a7d91cec909","claim-e32918d9fea1dabfb28f","claim-8e42b2f9f72cd9a24db7","claim-2e6101928b8375747b9e","claim-89495baad58b22768370"],"finding_ids":["F1"],"question":"What do clinicians need DAREON-NEC-1 to show about duration of cancer control, survival, quality of life, CRS and ICANS when adding obrixtamig to first-line chemotherapy for DLL3-positive advanced extrapulmonary neuroendocrine carcinoma?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One clinician balances unmet need against unproven benefit"},{"id":"section-2","level":2,"title":"One X account questions the meaning of unequal treatment durations"},{"id":"section-3","level":2,"title":"One clinician warns initial treatment choices can close trial access"},{"id":"section-4","level":2,"title":"One clinician pairs qualified CRS reassurance with intensive early monitoring"},{"id":"section-5","level":2,"title":"One clinician acknowledges local chemotherapy as a real alternative to enrollment"},{"id":"section-6","level":2,"title":"One X account anticipates testing and specialist-readiness barriers"},{"id":"section-7","level":2,"title":"One X account hopes lung-cancer maintenance findings can be replicated in epNEC"},{"id":"section-8","level":2,"title":"One X account reads development as competitive positioning"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"One clinician calls DAREON-7 activity “incredibly encouraging” but awaits randomized survival evidence"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T1","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":7},{"id":"F5","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":7},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-15T08:45:22.473973Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-15T09:01:24Z","record_hash":"2227cb2ffc27d345e4e19124189de2f8ae86d8a7f9aba4756ae779de53a1fac7","release_hash":"a361d727cdfef8c0a6badcf0b68982e8560b4fec2af0010248b32de95b6372ad","report_id":"erudio-nct07544654","run_id":"2ad58827-5eda-42e4-8b77-bec3291390ce","schema_version":"5.0","slug":"dareon-nec-1-nct07544654","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician described in the sources as presenting DAREON-NEC-1 sees chemotherapy resistance as a reason to investigate obrixtamig, while cautioning that patients may gain no benefit. Their participation advice weighs CRS observation and travel demands against uncertain personal benefit, with timely DLL3 assessment shaping access. Separately, a speaker whose clinical role is unstated questions how treatment duration would affect interpretation of a future survival advantage. This trial’s outcomes are not reported in the sources reviewed for this edition.","examples":[],"meta_description":"10 sources screened · 58 verified statements (41 from clinicians verified by NPI or staff page) from 6 sources · 9 findings. Updated Nov 15, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-15T09:01:24Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-15T18:58:18Z","kind":"routine","summary":"Corrected to match the delivered report: 58 verified statements (was 54); 41 statements from speakers with a confirmed clinical role (was 38); 9 findings (was 8); finding titles; per-finding counts; publication caveats beside findings; trial aspects; section headings; source breakdowns; the indications and therapeutic areas the report is listed under; the limitations; source quotations and links in the paid report. Finding titles on this page say what speakers discuss, with no word judging benefit or harm; the report keeps its own titles."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":10},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Not yet captured in this edition: a view on the promise of upfront obrixtamig plus chemotherapy evidence.","1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.","Discussion that does not name the trial may be missing from this edition.","4 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 40 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion, and the number of sources does not establish the number of independent clinical perspectives.","Most detailed eligibility, safety and participation guidance comes from a speaker, whom the source describes as presenting DAREON-NEC-1. Another speaker describes presenting the phase Ib DAREON-7 data underlying their favorable interpretation. These views should not be treated as independent external appraisals of those respective studies.","The relevant NCF conference passages do not establish the speaker's identity. They cannot safely be assigned to the person named in the video's title or description.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No DAREON-NEC-1 efficacy or safety readout appears in the material reviewed. DAREON-7 activity reports and extensive-stage small-cell lung cancer maintenance findings must not be substituted for its outcomes.","No protocol was listed in the registry information reviewed, no publication for the exact trial was identified, and no exact obrixtamig label was identified. Detailed protocol or current regulatory conclusions cannot be drawn from the commentary.","Discussion that never names the trial or recognizable aliases may be absent. Missing commentary cannot establish that clinicians have no view on an issue.","Recruitment and monitoring comparisons are time-specific source statements. They do not establish current site availability, eventual labeling or present-day comparative requirements.","Post and video publication dates do not establish presentation dates or changes of opinion."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":6},"count":6,"evidence_window":{"end":"2026-11-10","start":"2026-06-04"},"retrieval_snapshot":"2026-11-15T07:50:37.221971Z","timeline":[{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W39"},{"count":2,"week":"2026-W43"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07544654:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07544654:context","quote_policy":"short_quote_link_out"},{"id":"openfda:48aa7ef3-9f44-2a08-e054-00144ff88e88:20261106","quote_policy":"short_quote_link_out"},{"id":"openfda:4f850eb2-3542-43a0-90e8-bb37fa05cf15:20261109","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065201614143869137:38f9f5a7-ac4d-45d7-b160-ef3f9f6e93a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095850540458463469:91313b49-c164-43bd-9e04-aea2e8c82480","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103184457062883343:5cbb0a12-2c77-48a1-8c1f-6ff2d7f64aa8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113636779240927326:b12ba82d-5302-4f9b-95e3-d1850aae7ca6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114030160114516402:f8c561d8-5635-4288-b595-07ca126eebdc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118756189710532787:9f8f7f61-fa04-4fb0-85fc-08e0b2063f50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2119154685588431148:a0ee8684-b57e-4188-af09-471169fdb6bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120229927845044362:70ed8d4e-c613-47d9-84ce-dca0713dbe5a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:6Qt8nDQ8oEQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SjABtPcGEds","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-11-10","start":"2026-06-04"},"retrieval_snapshot":"2026-11-15T07:50:37.221971Z","timeline":[{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W39"},{"count":2,"week":"2026-W43"},{"count":2,"week":"2026-W45"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":44}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: obrixtamig","status":"unmapped"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"reason":"Unmapped registry intervention: etoposide","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Neuroendocrine carcinoma","slug":"neuroendocrine-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"DAREON-NEC-1","aliases":["DAREON-NEC-1","DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas"],"brief_title":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Extrapulmonary Neuroendocrine Cancer (epNEC)"],"display_condition":"first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas","display_interventions":[["obrixtamig"]],"enrollment":{"count":390,"type":"ESTIMATED"},"interventions":[{"name":"Obrixtamig","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Etoposide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ventana DLL3 RxDx assay","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DEVICE"}],"nct_id":"NCT07544654","official_title":"A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-12-13","type":"ESTIMATED"},"primary_endpoints":[{"description":"defined as the time from randomisation until death from any cause","measure":"Overall survival (OS)","timeFrame":"Up to 38 months"}],"registered_date":{"date":"2026-04-22","type":"ACTUAL"},"registry_last_updated":"2026-11-10","registry_url":"https://clinicaltrials.gov/study/NCT07544654","short_name":"DAREON-NEC-1","short_name_basis":"canonical_name","sponsor":"Boehringer Ingelheim","start_date":{"date":"2026-07-10","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"1438-0011","type":"sponsor_study_id"},{"domain":"CTIS","id":"2025-523869-22-00","type":"registry"},{"domain":"WHO International Clinical Trials Registry Platform (ICTRP)","id":"U1111-1328-6623","type":"registry"}],"study_type":"INTERVENTIONAL"}}}